Anti-programmed cell death protein 1 (anti-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) monoclonal antibodies (mAbs) have revolutionized anticancer treatment. However, there are still many patients who do not respond or acquire resistance to these treatments. Learn more about inhibitory checkpoint molecules: https://immune-checkpoint.crea....tive-biolabs.com/imm
Beğen
Yorum Yap
Paylaş
